Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
Cipla
Novartis
Baxter
Colorcon
Express Scripts
Federal Trade Commission
Daiichi Sankyo
Julphar

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,034,054

« Back to Dashboard

Summary for Patent: 6,034,054
Title: Stable insulin formulations
Abstract:The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.
Inventor(s): DeFelippis; Michael Rosario (Indianapolis, IN), Dobbins; Michael Allen (Lebanon, IN), Frank; Bruce Hill (Indianapolis, IN), Li; Shun (Indianapolis, IN), Rebhun; Dawn Marie (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/096,247
Patent Claim Types:
see list of patent claims
Formulation; Use;

Drugs Protected by US Patent 6,034,054

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly And Co HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747-001 May 26, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS. ➤ Sign Up
Eli Lilly And Co HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747-001 May 26, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF. ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,034,054

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,551,992 Stable insulin formulations ➤ Sign Up
6,906,028 Stable insulin formulations ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,034,054

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 012894 ➤ Sign Up
Austria 226088 ➤ Sign Up
Austria 329612 ➤ Sign Up
Australia 734781 ➤ Sign Up
Australia 7837798 ➤ Sign Up
Brazil 9810116 ➤ Sign Up
Canada 2295140 ➤ Sign Up
China 1266371 ➤ Sign Up
China 1293916 ➤ Sign Up
Colombia 4750643 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Healthtrust
McKinsey
Moodys
Fuji
Fish and Richardson
US Army
Boehringer Ingelheim
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot